Literature DB >> 21704160

Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model.

Elke Eggenhofer1, Philipp Renner, Yorick Soeder, Felix C Popp, Martin J Hoogduijn, Edward K Geissler, Hans J Schlitt, Marc H Dahlke.   

Abstract

BACKGROUND: Mesenchymal stem cells (MSCs) can be used for immunomodulation therapy after solid organ transplantation. Here, we focus on the immunoregulatory potential of combination therapies of MSCs and classic pharmacotherapy to mediate acceptance of solid organ grafts.
METHODS: To determine which drugs influence the immunosuppressive effect of MSCs, we assessed the interaction of MSCs and common clinical immunosuppresants (MMF, sirolimus [Srl], and ciclosporin A [CiA]) in a parent-into-F1 cell transfer model. In this model, the transfer of parental strain T cells into semi-allogeneic F1 recipients induces a graft-versus-host reaction (GvHR). Re-isolated CFSE-labelled T lymphocytes were analyzed by flow cytometry. These findings were compared to a fully allogeneic heart transplantation model.
RESULTS: We found that MSC treatment alone had no significant effect on allograft survival of heterotopic heart grafts. However, MSCs combined with short-term mycophenolate mofetil (MMF) significantly prolonged graft survival. Quantitative analysis of three different MSC - drug combinations in the F1 model revealed, that only the MSC-MMF combination led to a super-additive immunosuppressive effect. We also investigated the effect of MMF and CiA on IFNγ production of stimulated lymphocytes and found that MMF left the expression of IFNγ unaffected, whereas CiA completely abolished the production of IFNγ.
CONCLUSION: Our data show that the type of concurrent immunosuppression strongly influences the immunosuppressive effect of MSC, most likely through differential secretion of IFNγ. A regimen combining MSCs and MMF was most immunosuppressive.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704160     DOI: 10.1016/j.trim.2011.06.002

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  27 in total

1.  Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Authors:  Federica Casiraghi; Marta Todeschini; Nadia Azzollini; Paolo Cravedi; Paola Cassis; Samantha Solini; Sonia Fiori; Cinzia Rota; Aida Karachi; Camillo Carrara; Marina Noris; Norberto Perico; Giuseppe Remuzzi
Journal:  Transplantation       Date:  2019-06       Impact factor: 4.939

Review 2.  Rationale for the potential use of mesenchymal stromal cells in liver transplantation.

Authors:  Morgan Vandermeulen; Céline Grégoire; Alexandra Briquet; Chantal Lechanteur; Yves Beguin; Olivier Detry
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

3.  Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations.

Authors:  Michaela Hajkova; Barbora Hermankova; Eliska Javorkova; Pavla Bohacova; Alena Zajicova; Vladimir Holan; Magdalena Krulova
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 4.  Mesenchymal stem cells: Potential role in corneal wound repair and transplantation.

Authors:  Fei Li; Shao-Zhen Zhao
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

5.  Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus.

Authors:  Jianyong Xu; Jieting Chen; Wenlei Li; Wei Lian; Jieyong Huang; Baoyu Lai; Lingyun Li; Zhong Huang
Journal:  J Am Soc Nephrol       Date:  2019-10-11       Impact factor: 10.121

6.  iPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation.

Authors:  Pan-Pan Cheng; Xiao-Cun Liu; Peng-Fei Ma; Chang Gao; Jia-Li Li; Ying-Ying Lin; Wei Shao; Shuo Han; Bin Zhao; Lu-Min Wang; Jia-Zhao Fu; Lu-Xi Meng; Qing Li; Qi-Zhou Lian; Jun-Jie Xia; Zhong-Quan Qi
Journal:  Stem Cells Dev       Date:  2015-05-18       Impact factor: 3.272

Review 7.  Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation.

Authors:  Urvashi Kaundal; Upma Bagai; Aruna Rakha
Journal:  J Transl Med       Date:  2018-02-15       Impact factor: 5.531

8.  Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site.

Authors:  Moufida Ben Nasr; Andrea Vergani; James Avruch; Liye Liu; Eirini Kefaloyianni; Francesca D'Addio; Sara Tezza; Domenico Corradi; Roberto Bassi; Alessandro Valderrama-Vasquez; Vera Usuelli; James Kim; Jamil Azzi; Basset El Essawy; James Markmann; Reza Abdi; Paolo Fiorina
Journal:  Acta Diabetol       Date:  2015-03-27       Impact factor: 4.280

Review 9.  Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation.

Authors:  Kisha Nandini Sivanathan; Stan Gronthos; Darling Rojas-Canales; Benjamin Thierry; P Toby Coates
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

10.  Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.

Authors:  Marcella Franquesa; Martin J Hoogduijn; Marlies E Reinders; Elke Eggenhofer; Anja U Engela; Fane K Mensah; Joan Torras; Antonello Pileggi; Cees van Kooten; Bernard Mahon; Oliver Detry; Felix C Popp; Volker Benseler; Federica Casiraghi; Christian Johnson; Janis Ancans; Barbara Fillenberg; Olga delaRosa; Josep M Aran; Marieke Roemeling-van Rhijn; Marieke Roemeling-vanRhijn; Jef Pinxteren; Norberto Perico; Eliana Gotti; Bruno Christ; James Reading; Martino Introna; Robert Deans; Murat Shagidulin; Ramon Farré; Alessandro Rambaldi; Albert Sanchez-Fueyo; Natasha Obermajer; Andrey Pulin; Frank J M F Dor; Isabel Portero-Sanchez; Carla C Baan; Ton J Rabelink; Giuseppe Remuzzi; Michiel G H Betjes; Marc H Dahlke; Josep M Grinyó
Journal:  Transplantation       Date:  2013-08-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.